Search
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalHZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.
Zolazepam
go.drugbank.com/drugs/DB11555ExperimentalVet approvedIt is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.
PIK3CA
go.drugbank.com/drugs/DB14954InvestigationalPIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).
Hypoxanthine
go.drugbank.com/drugs/DB04076InvestigationalHypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.
Flurbiprofen axetil
go.drugbank.com/drugs/DB14938InvestigationalFlurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).
LY3884961
go.drugbank.com/drugs/DB17070InvestigationalLY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]
MBP-091
go.drugbank.com/drugs/DB17741ExperimentalMBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]
D-Proline
go.drugbank.com/drugs/DB02853ExperimentalThese amino acids may be of bacterial origin, but there is also evidence that they are endogenously produced through amino acid racemase activity [A19263].
Fosinoprilat
go.drugbank.com/drugs/DB14207ExperimentalFosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.
AG0302-COVID19
go.drugbank.com/drugs/DB16435InvestigationalSponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].